Sarah A.Gaskell

Associate

Washington + 1.202.879.3682

Sarah Gaskell focuses her practice on the representation of clients in the health care and life sciences industries. She represents food, drug, and medical device manufacturers and hospitals, health systems, physician groups, and emerging digital health companies in complex regulatory, transactional, and compliance matters.

Sarah counsels life sciences clients on issues associated with clinical research and the regulation of food, drugs, and medical devices by the Food and Drug Administration (FDA), including product promotion and advertising, good manufacturing practices, product recalls, FDA inspections, and enforcement actions. She also provides regulatory and transactional due diligence support in life sciences M&A and other transactions.

Sarah's experience includes guiding clients through direct-to-consumer telemedicine, licensure, patient consent, remote supervision, and corporate practice of medicine issues. She also supports health care clients engaged in M&A and other strategic transactions, including physician practice and hospice acquisitions and private equity investments, and is involved in structuring various management service agreements and other arrangements to provide professional, management, or administrative services.

Sarah maintains an active pro bono practice, including serving as a guardian ad litem and representing clients in Section 1983 proceedings.

Sarah is a member of the Food and Drug Law Institute and the American Health Lawyers Association.

Experience

  • CDPQ leads $125 million Series D financing of Soli OrganicJones Day advised CDPQ as lead investor in the $125 million Series D financing of Soli Organic, the nation's only soil-based, indoor farming company delivering 100% USDA certified organic produce.
  • Student resolves lawsuit against American University and D.C. Metropolitan Police Department over incident with university policeMs. Wheeler and American University announce that they have mutually resolved her lawsuit against the University.
  • Nurx merges with Thirty MadisonJones Day provided healthcare and data privacy counsel to Nurx in connection with its merger with Thirty Madison, a leading digital healthcare company operating across the U.S.
  • STERIS sells renal business to EvoquaJones Day advised STERIS in the $196.3 million sale of its Renal Care business to Evoqua Water Technologies, a leading provider of mission-critical water and wastewater treatment solutions.
  • Morgan Stanley Capital Partners acquires Omega PackagingJones Day advised Morgan Stanley Capital Partners in the acquisition and financing by portfolio company Comar of Omega Packaging, a manufacturer of injection and blow molded products serving the pharmaceutical, nutraceutical, sports nutrition, and skin care markets.
  • Dorilton Capital acquires Homestead HospiceJones Day represented Dorilton Capital in the acquisition by portfolio company Traditions Health, LLC, a national hospice and home health provider, of Roswell, Georgia, based Homestead Hospice, a multi-state provider of hospice services.
  • Genesis Healthcare Partners creates partnership with Triton Pacific Capital Partners to form Urology Partners of AmericaJones Day represented Genesis Healthcare Partners, P.C., a large San Diego-based physician group specializing in comprehensive urologic care, including radiation oncology and gastroenterology, in its sale to Urology Partners of America, LLC, a newly-formed national urology platform backed by Triton Pacific Capital Partners.
  • MDLIVE sells company to Cigna's EvernorthJones Day advised MDLIVE in its sale to Cigna's health services subsidiary Evernorth.